AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap plasmid (retina-validated serotype AAV-RC plasmid)

GeneMedi’s AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap plasmid (retina-validated serotype AAV-RC plasmid), also named AAV2 variant (Y272F, Y444F, Y500F, Y730F)-RC plasmid, is part of AAV2 variant (Y272F, Y444F, Y500F, Y730F) packaging system. AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap plamid supplies the AAV2 Rep(replication) proteins and the AAV2 variant (Y272F, Y444F, Y500F, Y730F) capsid protein.

You can produce AAV2 variant (Y272F, Y444F, Y500F, Y730F) paticle in 293T cell line in high titer using GeneMedi’s AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap plasmid with GeneMedi’s AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

The tissue tropism of AAV2 variant (Y272F, Y444F, Y500F, Y730F) vector has been validated in retina (retinal ganglion cells) by both intravitreal injection and sub-retinal injection., with potential applications in retina gene therapy.

AAV2 capsid variant (Y272F, Y444F, Y500F, Y730F) tissue tropism and gene transduction
(serotype-specific AAV infection)

The tissue tropism of AAV2 variant (Y272F, Y444F, Y500F, Y730F) vector has been validated in retina (retinal ganglion cells) by both intravitreal injection and sub-retinal injection with potential applications in retina gene therapy.

Virus and titer: AAV2 variant (Y272F, Y444F, Y500F, Y730F) vector system, 1×10¹² vg/ml
Animal: mouse, C57, 2 months
Infection site: retina
Gene delivery method: subretinal cavity injection, 3μl
Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy